Patanjali Ayurved claims to cure coronavirus, Ayush Ministry puts a stop on the processings
Updated: Monday, June 29, 2020, 12:45 [IST]
On Tuesday, Patanjali Ayurved claimed to have discovered a medicine that could cure and prevent novel coronavirus in just seven days. Yoga guru Ramdev in a press conference released 'Coronil and Swasari' medicine that claimed almost 100% favorable results in just seven days. He said that the pharmaceutical company conducted a clinical case study and clinical controlled trial in which 69% of patients recovered in 3 days while 100% recovered in 7 days.
Ayush Ministry, which regulates Ayurvedic medicines, quickly responded by limiting the companies' publicity campaign until they could produce a detailed report on composition and testing for the medicine. They said no such claim could be made till the ministry examined the medicine.
Ramdev said that the medicine was developed in Patanjali Research Center, Haridwar, along with the National Institute of Medical Science collaboration, Jaipur. He said the controlled clinical study of these medicines was done in several cities after getting approval from the Clinical Trial Registry of India (CTRI).
Patanjali has priced the medicine at Rs 545, which will have a dosage of 30 days. It will be made available in Patanjali stores and through an online mobile app by next week. The Ayush ministry refused to comment on the medicine and said they are not aware of any scientific study behind the medicine and have asked Patanjali Ayurved to provide the details before moving forward. Patanjali says that the medicine is purely Ayurvedic containing Giloy, Tulsi, and Ashwagandha.
As soon as Patanjali made the announcement, the ministry said, "To make this ministry aware of the facts of the aforesaid news and verify the claims, Patanjali Ayurved has been asked to provide at the earliest details of the name and composition of the medicines being claimed for Covid treatment; site(s)/hospital(s), where the research study was conducted for Covid-19; protocol, sample size, Institutional Ethics Committee clearance, CTRI registration and results in data of the study." Patanjali is becoming a multimillion-dollar company with an annual turnover of Rs 10,500 crore; It bought the debt-ridden Ruchi Soya for Rs 4,350 crore competing with an organization like Adani Group.